Form 4: CRISPR Therapeutics Director Ali Behbahani Acquires Stock Options

Director Ali Behbahani acquired 13,000 stock options in CRISPR Therapeutics AG on May 30, 2024, according to a recent SEC filing.

Summary

• Ali Behbahani, a director of CRISPR Therapeutics AG, reported the acquisition of 13,000 stock options on May 30, 2024.
• The options have an exercise price of $54.06.
• The options vest in 12 equal monthly installments starting May 31, 2024, and ending on the earlier of the one-year anniversary of the grant date or the date of the 2025 Annual General Meeting of Shareholders.
• Behbahani also has a power of attorney designating Zachary Bambach, Nicole Hatcher, and Stephanie Brecher to act on his behalf for SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing detailing stock option grants, which is a common practice. There's no indication of positive or negative sentiment from the document itself.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the options extends into the future.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies like CRISPR Therapeutics. It provides transparency into the holdings and transactions of company insiders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in biotech companies like CRISPR Therapeutics.
• Companies such as Intellia Therapeutics and Editas Medicine also utilize stock options as part of their compensation packages.
• The vesting schedule of 12 months is fairly standard in the industry.

Key Dates